169 citations
,
June 1998 in “Journal of Investigative Dermatology” This study found no significant genetic association between the 5α-reductase enzyme genes and male pattern baldness, suggesting a polygenic etiology rather than simple inheritance.
416 citations
,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
11 citations
,
August 1997 in “Expert Opinion on Therapeutic Patents” This review discusses nearly 70 patent applications for the treatment of androgenetic alopecia and other hair conditions, highlighting the mechanisms of action explored but reports no clinical results.
81 citations
,
February 1997 in “Journal of Investigative Dermatology” This study suggests that minoxidil activates PGHS-1, which may explain its hair growth-stimulating effects and could aid in designing more potent hair growth-promoting drugs.
19 citations
,
January 1997 in “Endocrinology” This study observed that testosterone inhibits hair follicle epithelial cell proliferation in adult stumptailed macaques only when dermal papilla cells from bald scalps are present, with antiandrogen RU 58841 reversing this effect.
234 citations
,
December 1996 in “Journal of The American Academy of Dermatology” The authors concluded that chronic telogen effluvium in middle-aged women presents distinct clinical and histological features that differ from androgenetic alopecia and acute telogen effluvium.
40 citations
,
January 1996 in “Journal of Dermatological Treatment” This study found that using an antimicrobial lotion for 18 months may reduce inflammation and potentially partially reverse hair loss in men with androgenetic alopecia.
24 citations
,
March 1995 in “British Journal of Dermatology” This study reported that etretinate treatment leads to increased hair shedding due to a sustained decrease in anagen duration, with an arrest at the onset of anagen and a follicular anchorage defect in telogen contributing to alopecia.
80 citations
,
January 1995 in “The American Journal of Medicine” Hair loss in androgenetic alopecia is caused by genetic factors and androgen excess, and can be treated with combined therapies.
27 citations
,
September 1994 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that relatively low concentrations of 1,25(OH)2D3 stimulated human hair follicle and fiber growth, while higher concentrations inhibited growth in a whole-organ culture system.
5 citations
,
January 1994 in “Dermatology” This study found that severe forms of alopecia areata showed increased activated T cells and natural killer cells, which decreased after corticosteroid treatment, correlating with disease activity and hair regrowth.
309 citations
,
May 1993 in “Journal of The American Academy of Dermatology” This study concluded that horizontal sections of scalp biopsy specimens provide more diagnostic information for male pattern androgenetic alopecia than vertical sections and can predict hair regrowth potential following topical minoxidil therapy.
77 citations
,
January 1993 in “Skin Pharmacology and Physiology” In this study, topically applied glucocorticosteroids were found to block hair growth at the stage of hair formation, but not the initiation of hair growth, in a mouse model.
42 citations
,
December 1990 in “The Journal of Dermatologic Surgery and Oncology” This study found decreased hair density and altered follicular architecture in the balding frontal scalp of patients with androgenic alopecia, with increased vellus hairs noted.
94 citations
,
August 1975 in “Journal of Cutaneous Pathology” In this study, the researchers observed that male pattern alopecia is characterized by miniature follicles, enlarged sebaceous glands, and an increased number of mast cells, without significant abnormalities in enzyme activity.